CSRT.L Regulatory News (CSRT)

22 June 2016

Consort Medical plc

Notification of Transactions of Directors or

Persons Discharging Managerial Responsibility and Connected Persons

DTR 3.1.4

On 21 June 2016 pursuant to the rules of the Consort Medical plc Deferred Bonus Plan the following Directors/persons discharging managerial responsibilities ("PDMRs") of Consort Medical plc (the "Company"), were granted awards over ordinary shares at a share price of £9.743 ("Shares") in the Company in respect of the financial year 2015/16 as detailed against their name below:

Deferred Bonus Share Award

Each award was granted as a nil cost option.

Enquiries: J Ilett 01442 867920

Consort Medical plc is a leading, global, single source pharma services drug and delivery device company. We are at the leading edge of innovation and we are committed to investing in patient, clinician and customer driven innovation to create new treatments, new markets and new opportunities.  

Our businesses

Bespak is a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, injectables and ocular products, and the manufacture of devices for the point of care diagnostics market. www.bespak.com.

Aesica is a leading provider of finished dose and active pharmaceutical ingredient (API) development and manufacturing services to pharmaceutical partners. www.aesica-pharma.com. 

We employ more than 2000 people globally of which 1400 are located in the UK. We have UK facilities in King's Lynn, Cambridge, Nelson, Milton Keynes, Cramlington, Queenborough and Hemel Hempstead, German facilities in Monheim and Zwickau and a facility in Pianezza, Italy. Consort Medical is a public company quoted on the premium list of the London Stock Exchange (LSE: CSRT). www.consortmedical.com.